Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 6
States / cities: Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more

Conditions: Sarcoidosis
Interventions: Placebo, Golimumab, Ustekinumab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more

Conditions: Chronic Inducible Urticaria
Interventions: barzolvolimab, Matching Placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Montgomery, Alabama • Paradise Valley, Arizona + 13 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebos; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more

Conditions: Atopic Dermatitis
Interventions: Oral EP262, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more

Conditions: Allergic Contact Dermatitis
Interventions: Panels 1.3, 2.2 and 3.2 experimental allergens; Diagnostic Test
Lead sponsor: Allerderm; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: San Diego, California • Aurora, Colorado • Louisville, Kentucky + 1 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 0 Months to 17 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Northbrook, Illinois • New York, New York

Conditions: Eczema, Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 530 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Clobetasol propionate 0.05% Topical Oil; Drug
Lead sponsor: Hill Dermaceuticals, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Sanford, Florida • Savannah, Georgia • Philadelphia, Pennsylvania + 3 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more

Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions: Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care; Combination Product · Other
Lead sponsor: Kari Nadeau, MD, PhD; Other
Eligibility: 1 Week to 12 Weeks
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more

Conditions: Atopic Dermatitis
Interventions: Barzolvolimab, Matching placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions: PBA-0405; Drug
Lead sponsor: Pure Biologics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Atopic Dermatitis
Interventions: abrocitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 21
States / cities: Birmingham, Alabama • Lancaster, California • Long Beach, California + 16 more

Conditions: Acute Otitis Media, Allergic Rhinitis, Sinusitis, Constipation, Pharyngitis, Croup, Urticaria, Bronchiolitis
Interventions: Electronic point-of-care delivery system; Device
Lead sponsor: University of Washington; Other
Eligibility: 0 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2003
U.S. locations: 2
States / cities: Seattle, Washington • Skagit Valley, Washington

Conditions: Pruritus, Atopic Dermatitis
Interventions: Asimadoline, Placebo; Drug
Lead sponsor: Tioga Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more

Conditions: Atopic Dermatitis
Interventions: Q301 Cream, Vehicle; Drug
Lead sponsor: Qurient Co., Ltd.; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriasis, Atopic Dermatitis
Interventions: BMX-010, Placebo; Drug
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Encino, California • Denver, Colorado • Englewood, Colorado + 7 more

Conditions: Progressive Pulmonary Fibrosis
Interventions: BMS-986278, BMS-986278 Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more

Conditions: Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections
Interventions: Retapamulin (Altabax); Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 9 Months to 98 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: DSXS, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Atopic Dermatitis
Interventions: Placebo, ZPL389 3mg, ZPL389 10mg, ZPL389 30mg, ZPL389 50mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Litchfield Park, Arizona • Fountain Valley, California • San Diego, California + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions: PBA-0111; Drug
Lead sponsor: Pure Biologics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Hereditary Angioedema
Interventions: KVD900 600 mg, Drug: KVD900 300 mg; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more

Search by objective public record fields.

VCRC Tissue Repository

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Seal, Stopping Eczema and Allergy Study

A Study of Barzolvolimab in Patients With Atopic Dermatitis

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

A Trial of Point of Care Information in Ambulatory Pediatrics

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial